For second-line treatment of metastatic HER2-positive breast cancer, the new-generation antibody drug conjugate (ADC) trastuzumab deruxtecan-nxki (T-DXd) is far more effective than the older-generation ADC trastuzumab emtansine (T-DM1), according to data from the first head-to-head comparison of ADCs for any malignancy, not just breast cancer.
For the primary outcome of progression-free survival (PFS), the risk reduction was more than 70% (hazard ratio [HR], 0.284), showing statistical